723
Panorama Actual del Medicamento
REVISIÓN
Bibliografía
1
Organización Mundial de la Salud (OMS).
Cefaleas; notas des
criptivas. Octubre 2012.
heets/fs277/es/index.html
2
Vos T, Flaxman AD, Naghavi M, Lozano R, et al.
Years lived
with disability (YLD) for 1160 sequelae of 289 diseases and injuries
1990–2010: A systematic analysis for the global burden of disease
study 2010.
Lancet
2012; 380: 2163–96.
3
Headache Classification Committee of the International Hea
dache Society (IHS).
The International Classification od Heada
che Disorders, 3er edition (beta version).
Cephalalgia
2013; 33(9):
629-808. DOI: 10.1177/0333102413485658 cep.sagepub.com
4
ArrudaMA, Guidetti V, Galli F, et al.
Primary headaches in child
hood – A population-based study.
Caphalalgia
2010; 30: 1056-64.
5
Salhofer-Polanyi S, Frantal S, Brannath W, et al.
Prospective
analysis of factors related to migraine aura – The PAMINA Study.
Headache
2012; 52: 1236–45.
6
EriksenMK, Thomsen LL, Olesen J.
Implications of clinical subty
pes of migraine with aura.
Headache
2006; 46: 286–97.
7
KirchmannM, Thomsen LL, Olesen J.
Basilar-type migraine: Cli
nical, epidemiologic, and genetic features.
Neurology
2006; 66:
880–6.
8
Hansen JM, Thomsen LL, Olesen J, et al.
Coexisting typical
migraine in familial hemiplegic migraine.
Neurology
2010; 74:
594–600.
9
Grosberg BM, Solomon S, Friedman DI, Lipton RB.
Retinal mi
graine reappraised.
Cephalalgia
2006; 26: 1275–86.
10
Buse DC, Manack AN, Fanning KM, et al.
Chronic migraine
prevalence, disability, and sociodemographic factors. Results from
the American Migraine Prevalence and Prevention Study.
Heada-
che
2012; 52: 1456–70.
11
Perucca P, Terzaghi M, Manni R.
Status epilepticus migrainosus:
Clinical, electrophysiologic, and imaging characteristics.
Neurology
2010; 75: 373–4.
12
Wang YF, Fuh JL, Chen WT, Wang SJ.
The visual aura rating
scale as an outcome predictor for persistent visual aura without
infarction.
Cephalalgia
2008; 28: 1298–304.
13
Bono G, Minonzio G, Mauri M and Clerici AM.
Complications
of migraine: Migrainous infarction.
Clin Exp Hypertens
2006; 28:
233–42.
14
Belcastro V, Striano P, Kasteleijn-Nolst Trenite DG, et al.
Migralepsy, hemicrania epileptica, post-ictal headache and‘ictal
epileptic headache’: A proposal for terminology and classification
revision.
J Headache Pain
2011; 12: 289–94.
15
Drossman DA, Dumitrascu DL.
Rome III: New standard for
functional gastrointestinal disorders.
J Gastrointestin Liver Dis
2006;
15: 237–41.
16
Drigo P, Carli G, Laverda AM.
Benign paroxysmal vertigo of
childhood.
Brain Dev (Netherlands)
2001; 23: 38–41.
17
Rosman NP, Douglass LM, Sharif UM, Paolini J.
The neurology
of benign paroxysmal torticollis of infancy: Report of 10 new cases
and review of the literature.
J Child Neurol
2009; 24: 155–60.
18
Irimia Sieira P, Martínez-Vila E.
Terapéutica de la migraña y de
otras cefaleas. En:
Terapéutica farmacológica de los trastornos del
sistema nervioso. Programa de Actualización en Farmacología y
Farmacoterapia
. Madrid: Consejo General de Colegios Oficiales
de Farmacéuticos; 2012. pp. 109-22.
19
Grupo de Cefalea de la Sociedad Española de Neurología.
Migraña. En:
Actitud diagnóstica y terapéutica en la cefalea. Reco-
mendaciones 2006.
Ergon; Madrid, 2006.; pp. 19-53.
20
BrandesJL.
Migraine inwomen.
Continuum(MinneapMinn).
2012;
18(4): 835-52. doi: 10.1212/01.CON.0000418646.70149.71.
21
Nappi RE, Terreno E, Sances G, Martini E, Tonani S, Santa
maria V, Tassorelli C, Spinillo A.
Effect of a contraceptive pill
containing estradiol valerate and dienogest (E2V/DNG) in women
with menstrually-related migraine (MRM).
Contraception
. 2013
Feb 28. doi:pii: S0010-7824(13)00045-0.10.1016/j.contracep
tion.2013.02.001.
22
Cuéllar Rodríguez S.
Fármacos analgésicos. En:
Terapéutica far-
macológica de los trastornos del sistema nervioso.
Programa de
Actualización en Farmacología y Farmacoterapia. Madrid: Consejo
General de Colegios Oficiales de Farmacéuticos; 2012. pp. 1-80.
23
Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Láinez M,
Henry P, Diener H,Schoenen J, Ferrari MD, Goadsby PJ.
Ergo
tamine in the acute treatment of migraine: a review and European
consensus.
Brain
. 2000; 123 (Pt 1): 9-18.
24
Rabasco Álvarez AM, González Rodríguez ML.
Aspectos ga
lénicos de los medicamentos que actúan en el sistema nervioso
central. En:
Terapéutica farmacológica de los trastornos del sistema
nervioso
. Programa de Actualización en Farmacología y Farmaco
terapia. Madrid: Consejo General de Colegios Oficiales de Farma
céuticos; 2012. pp. 437-76.
25
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB.
Triptans (seroto
nin, 5-HT1B/1D agonists) in migraine: detailed results and methods
of a meta-analysis of 53 trials.
Cephalalgia
. 2002; 22(8): 633-58.
26
Ho TW, Fan X, Rodgers A et al.
Age effects on placebo response
rates in clinical trials of acute agents for migraine: pooled analysis
of rizatriptan trials in adults.
Cephalalgia.
2009; 29(7):711-8. doi:
10.1111/j.1468-2982.2008.01788.x.
27
Elkind AH, O´carroll P, Blumenfeld A, et all.
A series of three
sequential, randomized, controlled studies of repeated treatments
with botulinum toxin type a for migraine prophylaxis.
J Pain
2006;
7(10): 688-96.
28
Lipton R, Dodick D, Silberstein S, et al.
Single-pulse transcra
nial magnetic stimulation for acute treatment of migraine with
aura: a randomised, double-blind, parallel-group, sham-contro
lled trial.
Lancet Neurol
2010; 9(4):373-80. doi: 10.1016/S1474-
4422(10)70054-5
29
Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White
AR.
Acupuncture for migraine prophylaxis.
Cochrane Database
Syst Rev
. 2009 Jan 21;(1):CD001218. doi: 10.1002/14651858.
CD001218.pub2.
30
Sullivan E, Bushnell C.
Management of menstrual migraine: a
review of current abortive and prophylactic therapies.
Curr Pain
Headache Rep.
2010; 14(5): 376-84. doi: 10.1007/s11916-010-
0138-2.
31
El-Chammas K, Keyes J, Thompson N, Vijayakumar J, Becher
D, Jackson JL.
Pharmacologic treatment of pediatric headaches: a
meta-analysis.
JAMA Pediatr
. 2013; 167(3): 250-8. doi: 10.1001/
jamapediatrics.2013.508.
32
Sarchielli P, Mancini ML, Calabresi P.
Practical considerations
for the treatment of elderly patients with migraine.
Drugs Aging
.
2006; 23(6): 461-89.
33
Mateos V, Porta-Etessam J, Armengol-Bertolín S, Larios C,
García M; en representación de los investigadores del estu
dio PRIMERA.
Situación de partida y abordaje asistencial de la mi
graña en las consultas de neurología de España. Estudio PRIMERA.
Rev Neurol
2012; 55: 577-84.
34
Mehuys E, Paemeleire K, Van Hees T, Christiaens T, Van Bor
tel LM, Van Tongelen I, De Bolle L, Remon JP, Boussery K.
Self-medication of regular headache: a community pharmacy-ba
sed survey.
Eur J Neurol
. 2012; 19(8): 1093-9. doi: 10.1111/j.1468-
1331.2012.03681.x.
35
Hoffmann W, Herzog B, Mühlig S, Kayser H, Fabian R,
Thomsen M, Cramer M, Fiß T, Gresselmeyer D, y Janhsen
K.
Pharmaceutical Care for Migraine and Headache Patients: A
Community-Based, Randomized Intervention.
Ann Pharmacother
.
2008; 42(12): 1804-13. doi:10.1345/aph.1K635
